In a report released yesterday, Danielle Antalffy from UBS reiterated a Buy rating on Boston Scientific, with a price target of $135.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Danielle Antalffy has given her Buy rating due to a combination of factors that indicate strong future growth potential for Boston Scientific. The company is expected to maintain double-digit sales growth and even faster EPS growth over the next few years, supported by an expanding product cycle and total addressable market. Despite recent share price declines, largely due to market rotation and concerns over 2026 growth comparisons, the upcoming Investor Day is seen as an opportunity for management to reassure investors of the company’s sustainable growth outlook.
Key growth drivers include a significant reacceleration in WATCHMAN sales, which could expand the total addressable market by five times, and sustained growth in other segments like Endoscopy and Urology/Pelvic Health. Additionally, there is potential for reacceleration in the CRM segment due to a new product cycle. Boston Scientific is expected to outline increasing exposure to higher growth markets, with a weighted average market growth rate exceeding 8%, and aims to achieve operating margin expansion that should drive substantial EPS growth. These factors contribute to the reaffirmation of the Buy rating and a price target of $135.
In another report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $115.00 price target.
BSX’s price has also changed slightly for the past six months – from $103.080 to $98.140, which is a -4.79% drop .